Dennis C. Daley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dennis C. Daley has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Antoine Douaihy
University of Pittsburgh
2 shared publications - Dennis M. Donovan
Alcohol and Drug Abuse Institute, University of Washington
2 shared publications Candace G. Hodgkins
Gateway Community Services , Jacksonville, Florida, USA
1 shared publication- D. Scott Wood
University of Pittsburgh Medical Center , Pittsburgh , Pennsylvania , USA
1 shared publication - David Loveland
Community Care Behavioral Health, 339 Sixth Avenue, Suite 1300, Pittsburgh, PA 15222, USA
1 shared publication - Duncan B. Clark
University of Pittsburgh
1 shared publication
Latest Publications
- 30 November 2014
- Published by Springer Nature
- p. 857-872
Twelve Step Facilitation as Behavioural Approach in Addiction Treatment
- 30 November 2014
- Published by Springer Nature
- p. 857-872
Twelve Step Facilitation as Behavioural Approach in Addiction Treatment
- 3 July 2014
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 10 (3) , 108-117
Contingency Management for Patients With Dual Disorders in Intensive Outpatient Treatment for Addiction
Objective: This quality improvement program evaluation investigated the effectiveness of contingency management for improving retention in treatment and positive outcomes among patients with dual disorders in intensive outpatient treatment for addiction. Methods: The effect of contingency management was explored among a group of 160 patients exposed to contingency management (n = 88) and not exposed to contingency management (no contingency management, n = 72) in a six-week partial hospitalization program. Patients referred to the partial hospitalization program for treatment of substance use and comorbid psychiatric disorders received diagnoses from psychiatrists and specialist clinicians according to the Diagnostic and Statistical Manual of the American Psychiatric Association. A unique application of the contingency management “fishbowl” method was used to improve the consistency of attendance at treatment sessions, which patients attended 5 days a week. Days attending treatment and drug-free days were the main outcome variables. Other outcomes of interest were depression, anxiety and psychological stress, coping ability, and intensity of drug cravings. Results: Patients in the contingency management group attended more treatment days compared to patients in the no contingency management group; M = 16.2 days (SD = 10.0) versus M = 9.9 days (SD = 8.5), respectively; t = 4.2, df = 158, p <.001. No difference was found between the treatment groups on number of drug-free days. Psychological stress and drug craving were inversely associated with drug-free days in bivariate testing (r = −.18, p <.02; r = −.31, p <.001, respectively). Treatment days attended and drug craving were associated with drug-free days in multivariate testing (B =.05, SE =.01, β =.39, t = 4.9, p <.001; B = −.47; SE =.12, β = −.30, t = −3.9, p <.001, respectively; Adj. R2 =.21). Days attending treatment partially mediated the relationship between exposure to contingency management and self-reported drug-free days. Conclusions: Contingency management is a valuable adjunct for increasing retention in treatment among patients with dual disorders in partial hospitalization treatment. Exposure to contingency management increases retention in treatment, which in turn contributes to increased drug-free days. Interventions for coping with psychological stress and drug cravings should be emphasized in intensive dual diagnosis group therapy.
- 3 July 2014
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 10 (3) , 108-117
Contingency Management for Patients With Dual Disorders in Intensive Outpatient Treatment for Addiction
Objective: This quality improvement program evaluation investigated the effectiveness of contingency management for improving retention in treatment and positive outcomes among patients with dual disorders in intensive outpatient treatment for addiction. Methods: The effect of contingency management was explored among a group of 160 patients exposed to contingency management (n = 88) and not exposed to contingency management (no contingency management, n = 72) in a six-week partial hospitalization program. Patients referred to the partial hospitalization program for treatment of substance use and comorbid psychiatric disorders received diagnoses from psychiatrists and specialist clinicians according to the Diagnostic and Statistical Manual of the American Psychiatric Association. A unique application of the contingency management “fishbowl” method was used to improve the consistency of attendance at treatment sessions, which patients attended 5 days a week. Days attending treatment and drug-free days were the main outcome variables. Other outcomes of interest were depression, anxiety and psychological stress, coping ability, and intensity of drug cravings. Results: Patients in the contingency management group attended more treatment days compared to patients in the no contingency management group; M = 16.2 days (SD = 10.0) versus M = 9.9 days (SD = 8.5), respectively; t = 4.2, df = 158, p <.001. No difference was found between the treatment groups on number of drug-free days. Psychological stress and drug craving were inversely associated with drug-free days in bivariate testing (r = −.18, p <.02; r = −.31, p <.001, respectively). Treatment days attended and drug craving were associated with drug-free days in multivariate testing (B =.05, SE =.01, β =.39, t = 4.9, p <.001; B = −.47; SE =.12, β = −.30, t = −3.9, p <.001, respectively; Adj. R2 =.21). Days attending treatment partially mediated the relationship between exposure to contingency management and self-reported drug-free days. Conclusions: Contingency management is a valuable adjunct for increasing retention in treatment among patients with dual disorders in partial hospitalization treatment. Exposure to contingency management increases retention in treatment, which in turn contributes to increased drug-free days. Interventions for coping with psychological stress and drug cravings should be emphasized in intensive dual diagnosis group therapy.
- 1 December 2013
- Published by The Journal of Food and Drug Analysis (JFDA), Food and Drug Administration, Taiwan (TFDA) in Journal of Food and Drug Analysis
- Vol. 21 (4) , S73-S76
Family and social aspects of substance use disorders and treatment
Substance use disorders (SUDs) are associated with numerous medical, psychiatric, psychological, spiritual, economic, social, family, and legal problems, creating a significant burden for affected individuals, their families, and society. This paper focuses on the effects of SUDs on family and social problems and emphasizes the need for clients in treatment to address these domains in their ongoing recovery. Individual, group, and family interventions to address these issues for clients with SUDs and their families are reviewed.
- 1 December 2013
- Published by The Journal of Food and Drug Analysis (JFDA), Food and Drug Administration, Taiwan (TFDA) in Journal of Food and Drug Analysis
- Vol. 21 (4) , S73-S76
Family and social aspects of substance use disorders and treatment
Substance use disorders (SUDs) are associated with numerous medical, psychiatric, psychological, spiritual, economic, social, family, and legal problems, creating a significant burden for affected individuals, their families, and society. This paper focuses on the effects of SUDs on family and social problems and emphasizes the need for clients in treatment to address these domains in their ongoing recovery. Individual, group, and family interventions to address these issues for clients with SUDs and their families are reviewed.
- 1 July 2012
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 8 (3) , 200-204
Mirtazapine in Comorbid Major Depression and Alcohol Dependence: An Open-Label Trial
Objective: This was a first pilot study evaluating the acute phase (8-week) efficacy of the antidepressant medication mirtazapine for the treatment of depressive symptoms and drinking of subjects with comorbid major depressive disorder and alcohol dependence (MDD/AD). We hypothesized that mirtazapine would demonstrate within-group efficacy for the treatment of both depressive symptoms and drinking in these subjects. Methods: We conducted a first open-label study of the second-generation antidepressant mirtazapine in 12 adult outpatient subjects with comorbid MDD/AD. The pharmacological profile of that medication is unique among antidepressants, unrelated to tricyclics or selective serotonin reuptake inhibitors. Results: Mirtazapine was well tolerated in this treatment population. Self-reported depressive symptoms decreased from 31.8 to 8.3 on the Beck Depression Inventory (BDI), a 74.0% decrease (p < .001), and drinking decreased from 33.9 to 13.3 drinks per week, a 60.8% decrease (p < .05). None of the subjects were employed full time at baseline, but 9 of the 12 (75%) were employed full time at the end the of study. Conclusions: These preliminary findings suggest efficacy for mirtazapine for treating both the depressive symptoms and excessive alcohol use of comorbid major depressive disorder and alcohol dependence. Double-blind studies are warranted to further clarify the efficacy of mirtazapine in this population.
- 1 July 2012
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 8 (3) , 200-204
Mirtazapine in Comorbid Major Depression and Alcohol Dependence: An Open-Label Trial
Objective: This was a first pilot study evaluating the acute phase (8-week) efficacy of the antidepressant medication mirtazapine for the treatment of depressive symptoms and drinking of subjects with comorbid major depressive disorder and alcohol dependence (MDD/AD). We hypothesized that mirtazapine would demonstrate within-group efficacy for the treatment of both depressive symptoms and drinking in these subjects. Methods: We conducted a first open-label study of the second-generation antidepressant mirtazapine in 12 adult outpatient subjects with comorbid MDD/AD. The pharmacological profile of that medication is unique among antidepressants, unrelated to tricyclics or selective serotonin reuptake inhibitors. Results: Mirtazapine was well tolerated in this treatment population. Self-reported depressive symptoms decreased from 31.8 to 8.3 on the Beck Depression Inventory (BDI), a 74.0% decrease (p < .001), and drinking decreased from 33.9 to 13.3 drinks per week, a 60.8% decrease (p < .05). None of the subjects were employed full time at baseline, but 9 of the 12 (75%) were employed full time at the end the of study. Conclusions: These preliminary findings suggest efficacy for mirtazapine for treating both the depressive symptoms and excessive alcohol use of comorbid major depressive disorder and alcohol dependence. Double-blind studies are warranted to further clarify the efficacy of mirtazapine in this population.
- Open Access
- 1 July 2011
- Published by Taylor & Francis in Journal of Groups in Addiction & Recovery
- Vol. 6 (3) , 228-244
A Combined Group and Individual 12-Step Facilitative Intervention Targeting Stimulant Abuse in the NIDA Clinical Trials Network: STAGE-12
- 1 July 2011
- Published by Taylor & Francis in Journal of Groups in Addiction & Recovery
- Vol. 6 (3) , 228-244
Open AccessA Combined Group and Individual 12-Step Facilitative Intervention Targeting Stimulant Abuse in the NIDA Clinical Trials Network: STAGE-12